Effects of nicotine on smooth pursuit eye movements in healthy non-smokers.


Journal

Psychopharmacology
ISSN: 1432-2072
Titre abrégé: Psychopharmacology (Berl)
Pays: Germany
ID NLM: 7608025

Informations de publication

Date de publication:
Jul 2019
Historique:
received: 26 09 2018
accepted: 06 03 2019
pubmed: 16 3 2019
medline: 5 11 2019
entrez: 16 3 2019
Statut: ppublish

Résumé

The non-selective nicotinic acetylcholine receptor (nAChR) agonist nicotine has been argued to improve attention via enhanced filtering of irrelevant stimuli. Here, we tested this hypothesis in the context of smooth pursuit eye movements (SPEMs), an oculomotor function previously shown to improve with nicotine in some but not all studies. In order to test whether nicotine improves performance particularly when the inhibition of distracting stimuli is required, SPEM was elicited in conditions with or without peripheral distractors. Additionally, different target frequencies were employed in order to parametrically vary general processing demands on the SPEM system. Healthy adult non-smokers (N = 18 females, N = 13 males) completed a horizontal sinusoidal SPEM task at different target frequencies (0.2 Hz, 0.4 Hz, 0.6 Hz) in the presence or absence of peripheral distractors in a double-blind, placebo-controlled, cross-over design using a 2 mg nicotine gum. Nicotine increased peak pursuit gain relative to placebo (p < .001), but an interaction with distractor condition (p = .001) indicated that this effect was most pronounced in the presence of distractors. Catch-up saccade frequency was reduced by nicotine (p = .01), particularly at higher target frequencies (two-way interaction, p = .04). However, a three-way interaction (p = .006) indicated that the reduction with nicotine was strongest at the highest target frequency (0.6 Hz) only without distractors, whereas in the presence of distractors, it was strongest at 0.4-Hz target frequency. There were no effects of nicotine on subjective state measures. Together, these findings support a role of both distractor inhibition and general processing load in the effects of nicotine on smooth pursuit.

Identifiants

pubmed: 30874860
doi: 10.1007/s00213-019-05223-1
pii: 10.1007/s00213-019-05223-1
doi:

Substances chimiques

Nicotinic Agonists 0
Nicotine 6M3C89ZY6R

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

2259-2271

Références

Psychophysiology. 1999 Mar;36(2):158-63
pubmed: 10194962
Eur Arch Psychiatry Clin Neurosci. 2000;250(5):221-5
pubmed: 11097164
Psychophysiology. 2001 Mar;38(2):325-33
pubmed: 11347877
Nicotine Tob Res. 2002 Feb;4(1):25-70
pubmed: 11906682
Biol Psychiatry. 2002 Oct 1;52(7):721-8
pubmed: 12372663
Hum Psychopharmacol. 2001 Jun;16(4):321-326
pubmed: 12404567
Psychophysiology. 2002 Nov;39(6):809-19
pubmed: 12462508
Neuropsychopharmacology. 2002 Dec;27(6):1056-70
pubmed: 12464463
Prog Brain Res. 2002;140:267-77
pubmed: 12508596
Psychiatry Res. 2003 Mar 25;117(3):223-36
pubmed: 12686365
Curr Drug Targets CNS Neurol Disord. 2002 Aug;1(4):423-31
pubmed: 12769614
Neuropsychopharmacology. 2003 Dec;28(12):2184-91
pubmed: 12968127
J Psychopharmacol. 2004 Dec;18(4):457-74
pubmed: 15582913
IDrugs. 2004 Dec;7(12):1096-103
pubmed: 15599803
Exp Brain Res. 2005 Jun;163(3):306-13
pubmed: 15654587
Neuropsychopharmacology. 2005 Apr;30(4):810-20
pubmed: 15668726
Am J Psychiatry. 2005 Feb;162(2):391-3
pubmed: 15677609
Neurosci Biobehav Rev. 2005;29(6):1021-34
pubmed: 15964073
Nicotine Tob Res. 2005 Jun;7(3):317-33
pubmed: 16085500
Biol Psychiatry. 2006 Apr 15;59(8):754-61
pubmed: 16259965
Psychopharmacology (Berl). 1991;104(4):536-40
pubmed: 1780425
Eur Arch Psychiatry Clin Neurosci. 2008 Sep;258(6):373-83
pubmed: 18437278
Brain Cogn. 2008 Dec;68(3):219-28
pubmed: 18835076
Brain Cogn. 2008 Dec;68(3):341-58
pubmed: 18842328
Brain Cogn. 2008 Dec;68(3):359-70
pubmed: 18845372
Brain Cogn. 2008 Dec;68(3):309-26
pubmed: 18848744
Brain Cogn. 2008 Dec;68(3):415-35
pubmed: 19028266
Neuroimage. 2009 Apr 1;45(2):549-61
pubmed: 19159693
Clin EEG Neurosci. 2009 Jan;40(1):11-20
pubmed: 19278128
J Psychopharmacol. 2011 Feb;25(2):239-48
pubmed: 19939874
Neuropsychopharmacology. 2010 Mar;35(4):938-42
pubmed: 19956085
Biol Psychiatry. 1991 Jan 1;29(1):82-8
pubmed: 2001447
Psychopharmacology (Berl). 2010 Jul;210(4):453-69
pubmed: 20414766
Curr Top Behav Neurosci. 2010;4:311-47
pubmed: 21312405
Biochem Pharmacol. 2011 Oct 15;82(8):943-51
pubmed: 21684262
Cereb Cortex. 2013 May;23(5):1179-89
pubmed: 22581848
J Abnorm Psychol. 1990 Nov;99(4):327-35
pubmed: 2266205
Front Behav Neurosci. 2012 Aug 28;6:53
pubmed: 22973209
Psychopharmacology (Berl). 2013 May;227(2):331-45
pubmed: 23430159
J Int Neuropsychol Soc. 2013 Mar;19(3):324-37
pubmed: 23448879
Neuropharmacology. 2014 Sep;84:111-22
pubmed: 23474015
J Comp Neurol. 2013 Dec 15;521(18):4124-44
pubmed: 23852922
Biochem Pharmacol. 2013 Oct 15;86(8):1089-98
pubmed: 23856288
Psychiatry Res. 2014 Jul 30;217(3):185-90
pubmed: 24721292
Hum Brain Mapp. 2015 Jan;36(1):340-53
pubmed: 25197013
Psychopharmacology (Berl). 2015 Apr;232(7):1269-77
pubmed: 25304866
Neuropharmacology. 2015 Sep;96(Pt B):289-301
pubmed: 25446570
Psychopharmacology (Berl). 2015 Jun;232(11):2017-28
pubmed: 25491929
Curr Top Behav Neurosci. 2015;23:103-35
pubmed: 25655889
Ann N Y Acad Sci. 2015 Sep;1349:64-82
pubmed: 26348486
Hum Brain Mapp. 2016 Nov;37(11):4047-4060
pubmed: 27342447
Neuroimage. 2016 Nov 1;141:52-59
pubmed: 27402599
Curr Alzheimer Res. 2017;14(4):377-392
pubmed: 27697062
Psychopharmacology (Berl). 2017 Apr;234(7):1093-1111
pubmed: 28150023
Eur Neuropsychopharmacol. 2019 Dec;29(2):235-246
pubmed: 30552041
Ann Neurol. 1988 Mar;23(3):238-41
pubmed: 3377447
Annu Rev Neurosci. 1987;10:97-129
pubmed: 3551767
Neuropharmacology. 1971 Mar;10(21):181-91
pubmed: 5093959
Neuropsychologia. 1971 Mar;9(1):97-113
pubmed: 5146491
J Physiol. 1984 Jun;351:217-50
pubmed: 6747865
Arch Gen Psychiatry. 1981 Sep;38(9):991-6
pubmed: 7283671
Acta Neurol Scand. 1995 May;91(5):335-45
pubmed: 7639062
Eur Arch Psychiatry Clin Neurosci. 1994;244(3):153-60
pubmed: 7803530
Psychopharmacology (Berl). 1996 Jan;123(1):55-63
pubmed: 8741955
Clin Pharmacol Ther. 1997 Mar;61(3):349-59
pubmed: 9084460
Clin Psychol Rev. 1997;17(5):451-78
pubmed: 9260037
J Neurosci. 1997 Oct 1;17(19):7490-502
pubmed: 9295395
Psychopharmacology (Berl). 1997 Aug;132(4):389-95
pubmed: 9298517
Neuropsychopharmacology. 1998 Mar;18(3):175-85
pubmed: 9471115
Exp Clin Psychopharmacol. 1998 May;6(2):209-16
pubmed: 9608353
J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57
pubmed: 9881538

Auteurs

Inga Meyhöfer (I)

Department of Psychology, University of Bonn, Kaiser-Karl-Ring 9, 53111, Bonn, Germany.
Department of Psychiatry and Psychotherapy, Otto Creutzfeldt Center for Cognitive and Behavioral Neuroscience, University of Muenster, Muenster, Germany.

Anna-Maria Kasparbauer (AM)

Department of Psychology, University of Bonn, Kaiser-Karl-Ring 9, 53111, Bonn, Germany.

Maria Steffens (M)

Department of Psychology, University of Bonn, Kaiser-Karl-Ring 9, 53111, Bonn, Germany.

Ulrich Ettinger (U)

Department of Psychology, University of Bonn, Kaiser-Karl-Ring 9, 53111, Bonn, Germany. ulrich.ettinger@uni-bonn.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH